LitAlert ~~ GeneLit.com

    • Loss-of-function variants in CTNNA1 detected on multigene panel testing in individuals with gastric or breast cancer.
    • Farengo Clark D, Michalski ST, Tondon R, Nehoray B, Ebrahimzadeh J, Hughes SK, Soper ER, Domchek SM, Rustgi AK, Pineda-Alvarez D, Anderson MJ, Katona BW.
    • Genet Med. 2020 Feb 13. doi: 10.1038/s41436-020-0753-1. [Epub ahead of print]
    • An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice—A Review.
    • Rainone M, Singh I, Salo-Mullen EE, Stadler ZK, O’Reilly EM.
    • JAMA Oncol. 2020 Feb 13. doi: 10.1001/jamaoncol.2019.5963. [Epub ahead of print]
    • Review
    • Facilitated referral pathway for genetic testing at the time of ovarian cancer diagnosis: uptake of genetic counseling and testing and impact on patient-reported stress, anxiety and depression.
    • Frey MK, Lee SS, Gerber D, Schwartz ZP, Martineau J, Lutz K, Reese E, Dalton E, Olsen A, Girdler J, Pothuri B, Boyd L, Curtin JP, Levine DA, Blank SV.
    • Gynecol Oncol. 2020 Feb 11. pii: S0090-8258(20)30007X doi: 10.1016/j.ygyno.2020.01.007. [Epub ahead of print]
    • MICA-129 Met/Val polymorphism could be a genetic biomarker for Familial Breast Cancer in the Tunisian population.
    • Ouni N, Ben Chaaben A, Ayari F, Douik H, Guizani I, Benammar-Elgaaied A, Guemira F, Tamouza R.
    • Int J Immunogenet. 2020 Feb 11. doi: 10.1111/iji.12480. [Epub ahead of print]
    • BRCA2 and RB1 loss responds to PARP inhibitors.
    • Fenner A.
    • Nat Rev Urol. 2020 Feb 11. doi: 10.1038/s41585-020-0293-0. [Epub ahead of print]
    • Review
    • Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel.
    • Lorusso D, Bologna A, Cecere SC, De Matteis E, Scandurra G, Zamagni C, Arcangeli V, Artioli F, Bella M, Blanco G, Cardalesi C, Casartelli C, De Vivo R, Di Napoli M, Gisone EB, Lauria R, Lissoni AA, Loizzi V, Maccaroni E, Mangili G, Marchetti C, Martella F, Naglieri E, Parolin V, Ricciardi G, Ronzino G, Salutari V, Scarfone G, Secondino S, Spagnoletti I, Tasca G, Tognon G, Guarneri V.
    • Support Care Cancer. 2020 Feb 11. doi: 10.1007/s00520-020-05320-4. [Epub ahead of print]
    • Guidelines
    • [Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications].
    • Koual M, Perkins G, Delanoy N, Crespel C, Medioni J, Nguyen-Xuan HT, Douay-Hauser N, Blons H, Le Frère-Belda MA, Molière D, Achen G, Nos C, Balaya V, Montero R, Laurent-Puig P, Bats AS.
    • Ann Pathol. 2020 Feb 8. pii: S0242-6498(20)30026-2. doi: 10.1016/j.annpat.2020.01.004. [Epub ahead of print]
    • Review, [Article in French]
    • PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation.
    • Min A, Im SA.
    • Cancers (Basel). 2020 Feb 8;12(2). pii: E394. doi: 10.3390/cancers12020394.
    • Genetic Predisposition to Breast and Ovarian Cancers: How Many and Which Genes to Test?
    • Angeli D, Salvi S, Tedaldi G.
    • Int J Mol Sci. 2020 Feb 8;21(3). pii: E1128. doi: 10.3390/ijms21031128.
    • Transmission of X-linked Ovarian Cancer: Characterization and Implications.
    • Etter JL, Moysich K, Kohli S, Lele S, Odunsi K, Eng KH.
    • Diagnostics (Basel). 2020 Feb 7;10(2). pii: E90. doi: 10.3390/diagnostics10020090.
    • Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
    • Valiakhmetova A, Gorelyshev S, Konovalov A, Trunin Y, Savateev A, Kram DE, Severson E, Hemmerich A, Edgerly C, Duncan D, Britt N, Huang RSP, Elvin J, Miller V, Ross JS, Gay L, McCorkle J, Rankin A, Erlich RL, Chudnovsky Y, Ramkissoon SH.
    • Oncologist. 2020 Feb;25(2):e198-e202. doi: 10.1634/theoncologist.2019-0603. Epub 2019 Oct 16.
    • In silico analysis for determining the deleterious nonsynonymous single nucleotide polymorphisms of BRCA genes.
    • Yadegari F, Majidzadeh K.
    • Mol Biol Res Commun. 2019 Dec;8(4):141-150. doi: 10.22099/mbrc.2019.34198.1420.